ATRA Atara Biotherapeutics, Inc.

MIXED Impact: 5/10 Insider Cluster (2 insiders)
Horizon days Filed May 7, 2026 Processed 29d 7h ago
Insider cluster: 2 insiders, $7.9M total
Latest settled — T+20d ⚠ clustered
ATRA ▼ -3.02% at T+20d
NEUTRAL call ✗ call lost -3.02% · α vs SPY -6.16% · entry $9.93 → $9.63
Next anchor: T+60d in 7w
Last close $9.58 (close Jun 8) · -3.52% from $9.93 entry
Entry anchored
May 6, 03:59 PM ET
via Databento tick
T+1d
-16.01%
call -16.01% · α -16.84%
$8.34
settled 5w ago
T+5d
+5.54%
call +5.54% · α +4.03%
$10.48
settled 28d ago
T+20d
-3.02%
call -3.02% · α -6.16%
$9.63
settled 6d ago
T+60d
call — · α —
in 7w

Price Chart

Loading chart...

Executive Summary

Atara Biotherapeutics saw a mixed insider cluster: 10% owner EcoR1 Capital bought $4.74M worth of shares, while director/10% owner Panacea Innovation sold $3.17M worth on the same day. The net $1.57M buying is modest relative to ATRA's $71M market cap (~2.2%), but the simultaneous insider buying and selling creates a conflicting signal that warrants caution.

Key Financial Metrics

Direction
mixed
Total Value
$1.6M
Insiders
2

Actionable Insight

The simultaneous large buy and sell by two major 10% owners creates a split signal. EcoR1's $4.74M purchase is a bullish vote of confidence, but Panacea's $3.17M sale suggests some insiders are taking profits. Given ATRA's small $71M market cap and the historical pattern of poor T+20 performance on prior calls, traders should wait for a clearer directional catalyst (e.g., earnings, pipeline update) before taking a position.

Key Facts

  • EcoR1 Capital purchased 507,407 shares at $9.35 for $4.74M on 2026-05-07
  • Panacea Innovation sold 313,446 shares at $10.10 for $3.17M on 2026-05-07
  • Net insider buying of ~$1.57M, representing ~2.2% of ATRA's $71M market cap
  • Both parties are 10% owners; no C-suite insiders traded
  • Historical calibration shows past neutral calls on ATRA had a 25% win rate at T+20 with avg alpha of -10.81%

Financial Impact

Net insider buying of ~$1.57M, ~2.2% of market cap

market capinsider ownership

Risk Factors

  • Insider selling by a 10% owner may signal lack of confidence in near-term prospects
  • ATRA's small market cap makes it highly volatile; past neutral calls have underperformed SPY by -10.81% at T+20
  • No C-suite participation reduces the signal strength of insider activity

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
70% bullish (10 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ATRA-1778539528445
7 reports for ATRA
Performance horizon
Filters
Rows
Reports for ATRA — sortable, filterable
Type Now
May 7, 2026
4w ago
8-K
NEUTRAL ★ 4/10
$9.93 $9.63▼ −3.02%▼ −6.16%$9.58 (−3.52%)
May 7, 2026
4w ago
Insider Cluster
MIXED ★ 5/10
$9.93 $9.63▼ −3.02%▼ −6.16%$9.58 (−3.52%)
Apr 24, 2026
6w ago
DEFA14A
NEUTRAL ★ 3/10
$4.99 $9.61▲ +92.59%▲ +87.63%$9.58 (+91.98%)
Mar 17, 2026
12w ago
S-3
NEUTRAL ★ 4/10
$5.00 $5.24▲ +4.80%▼ −1.25%$9.58 (+91.60%)
Mar 12, 2026
12w ago
8-K
NEUTRAL ★ 5/10
$6.90 $4.65▼ −32.61%▼ −34.58%$9.58 (+38.84%)
Mar 3, 2026
14w ago
8-K
MIXED ★ 6/10
$5.42 $4.73▼ −12.73%▼ −8.33%$9.58 (+76.75%)
Mar 2, 2026
14w ago
Insider Cluster
NEUTRAL ★ 2/10
$4.91 $4.32▼ −12.02%▼ −4.08%$9.58 (+95.11%)
Showing 7 of 7

US Market Status

Market Closed — Opens in 7h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access